Voyager Technologies Wins Contract for ISS Biopolymer Cancer Implant Study
MT newswire2026/10/06 14:0010:00 AM EDT, 10/06/2026 (MT Newswires) -- Voyager Technologies (VOYG) has secured a contract from the Center for the Advancement of Science in Space to manage Symphony Biosciences' biopolymer cancer implant experiment aboard the International Space Station, the company said Tuesday. Financial details weren't disclosed. Under the contract, Voyager is expected to adapt the experiment hardware for station equipment, support NASA safety reviews, manage launch integration and on-orbit operations, and help test SymphNode, a device designed to restore immune response by recruiting and activating T cells to fight cancer. Voyager will return the experiment samples and data after the study and provide post-flight and close-out reporting. Price: 30.93, Change: +0.73, Percent Change: +2.41
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Quantumrail Cancels 10 Billion Won Convertible Bond Offering
Crypto prices
More
